A phase 2 multi-center, open label long-term extension trial to assess the safety of oral UK-390 957 administered as required in adult men with premature ejaculation
Latest Information Update: 23 Nov 2012
At a glance
- Drugs UK 390957 (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Dec 2005 New trial record.